How to analyze the company?LEARNWhat should you know before buying?
Get a brief AI stock analysisSaves ~ 15 minutes of your time

AL

NASDAQ:ALPN
Get a brief AI stock analysisSaves ~ 15 minutes of your time

AL

Alpine Immune Sciences IncNASDAQ ALPN Stock Report

Get a brief AI stock analysis
Saves ~ 15 minutes of your time

Price

Market cap $B

Exchange

XNAS - Nasdaq

FAIR VALUE

Is ALPN undervalued compared to its fair value?

The fair value of ALPN stock is hidden USD. Relative to the market price of 0 USD Alpine Immune Sciences Inc is hidden.

Alpine Immune Sciences, Inc. is a development-stage pharmaceutical company, which engages in the discovery of protein-based immunotherapies to treat cancer and autoimmune and inflammatory diseases. The company is headqua...[More about valuation]

Alpine Immune Sciences Fair Value

hidden
UNLOCK
What is fair value?

Market cap:

4.457 $B

Price:

Fair value:

hidden

Max value:

hidden

Min value:

hidden

P/E:

hidden

EPS:

-0.28

FINANCIALS

Alpine Immune Sciences financial for reporting period

Income Statement

0.007 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.023 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.018 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
Revenue analysis

0.007 B 100%
-0.023 B -323%
-0.018 B -255%

Balance Sheet

0.37 B
0.33 B

Financial Position Analysis

Assets

0.37 B
Current Assets
0.31 B
Total non-current assets
0.065 B

Total current liabilities
0.032 B
Total non-current liabilities
0.0087 B

Cash Flow Statement

-0.028 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.028 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A

Alpine Immune Sciences fundamental analysis for trailing twelve months (TTM)

Profitability Indicators


Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Solvency Indicators


Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Efficiency Indicators

-15 %

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%
-467 %

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%
-12 %

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Dupont Analysis

Stability Indicators

STOCK ANALYSIS

Is ALPN attractive for investment based on fundamental analysis?

ALPN stock rating is hidden. Alpine Immune Sciences is a hidden by Eyestock methodology.

Get ALPN Stock Rating
to complete you analysis
UNLOCK
Learn more about quality score?

Net Profit Margin:

-65

Gross Margin:

CFO / Debt ratio:

hidden

Current ratio:

5.813

Debt / Equity ratio:

ROE:

-15

ROIC:

hidden

Stability Ratio (2y):

hidden

Stability Ratio (5y):

hidden

Earnings quality:

hidden

ALPN analysis by AI

Eyebot AI analysis

We carefully consider 10 indicators for ALPN to calculate the final rating score. Use AI leverage to quickly get the main conclusions before diving into the details

Alpine Immune Sciences Inc competitors

AB

ABBV

Abbvie Inc

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. The company is headquartered in North Chicago, Ill...

Discover

AM

AMGN

Amgen Inc

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. The Company...

Discover

VR

VRTX

Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs fo...

Discover

Alpine Immune Sciences Inc dividends

ALPN dividend metrics

Payout ratio
Dividend yield
Annual dividend
Dividend streak
Average dividend yield over 3 years
Average dividend yield over 5 years

Dividend per share

By years
By payments
1y
3y
5y
All time
This ticker has no dividend history

About ALPN stock

About the company Alpine Immune Sciences Inc

Market cap $B

4.457

Dividend yield

Shares outstanding

45.9144 B

Alpine Immune Sciences, Inc. is a development-stage pharmaceutical company, which engages in the discovery of protein-based immunotherapies to treat cancer and autoimmune and inflammatory diseases. The company is headquartered in Seattle, Washington and currently employs 85 full-time employees. The company went IPO on 2015-06-17. The firm is focused on discovering and developing protein-based immunotherapies to treat cancer and autoimmune and inflammatory diseases. The firm's scientific platform uses a directed evolution process to convert native immune system proteins from the immunoglobulin super family (IgSF) into multi-targeted therapeutics capable of modulating the human immune system. Its product candidates include ALPN-101, ALPN-202 and ALPN-303. ALPN-101 is a dual inducible T cell costimulator (ICOS) and cluster of differentiation 28 (CD28) antagonist intended for the treatment of autoimmune and inflammatory diseases. Its oncology program is ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor intended for the treatment of cancer. ALPN-303 is a dual B-cell cytokine antagonist for the treatment of B-cell mediated diseases.

ALPN profile

  • Ticker

    ALPN

  • Country

    USA

  • Exchange

    XNAS - Nasdaq

  • Report currency

    USD - US dollar

  • IPO date

    17 June 2015

  • Sector

    Healthсare

  • Industry

    Biotechnology

  • Employees

    85

  • City

    Seattle

  • Address

    188 East Blaine St., Suite 200

  • Cusip

    02083G100